Skip to main content

Advertisement

SpringerLink
Log in

Adjuvante Radiotherapie bei der multimodalen Behandlung resektabler Magenkarzinome – Kritik an den Schlussfolgerungen aus CRITICS?

Adjuvant radiotherapy in the multimodal treatment of resectable gastric cancer—criticism of the conclusions drawn from CRITICS?

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730

    Article  CAS  PubMed  Google Scholar 

  2. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20

    Article  CAS  PubMed  Google Scholar 

  3. Ychou M, Boige V, Pignon JP et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721

    Article  CAS  PubMed  Google Scholar 

  4. Leong T, Smithers BM, Michael M et al (2015) TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer 15:532

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Al-Batran S, Hofheinz R, Pauligk C et al (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 17:1697–1708

    Article  CAS  PubMed  Google Scholar 

  6. Zhu WG, Xua DF, Pu J et al (2012) A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol 2012(104):361–366

    Article  CAS  Google Scholar 

  7. Lee J, Lim DH, Kim S et al (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268–273

    Article  CAS  PubMed  Google Scholar 

  8. Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S‑1 versus surgery alone instage II or III gastric cancer. J Clin Oncol 29:4387–4393

    Article  CAS  PubMed  Google Scholar 

  9. Noh SH, Park SR, Yang HK et al (2014) Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5‑year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 15:1389–1396

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum für Strahlentherapie und Radioonkologie, Mozartstr. 30, 26655, Westerstede, Deutschland

    Robert Michael Hermann

  2. Klinik für Strahlentherapie und Spezielle Onkologie, Medizinische Hochschule Hannover, Hannover, Deutschland

    Hans Christiansen

Authors
  1. Robert Michael Hermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Christiansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Michael Hermann.

Ethics declarations

Interessenkonflikt

R.M. Hermann und H. Christiansen geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Cats A, Jansen EPM, van Grieken NCT et al (2018) Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 19(5):616–628

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hermann, R.M., Christiansen, H. Adjuvante Radiotherapie bei der multimodalen Behandlung resektabler Magenkarzinome – Kritik an den Schlussfolgerungen aus CRITICS?. Strahlenther Onkol 195, 86–89 (2019). https://doi.org/10.1007/s00066-018-1394-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-018-1394-z

Search

Navigation